Patents by Inventor William N. Haining

William N. Haining has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220081691
    Abstract: The present invention relates, in part, to methods of treating a subject with a condition that would benefit from an increased immune response comprising administering to the subject a therapeutically effective amount of an agent that inhibits PTPN2. The present invention also provides methods and compositions for perturbing gene expression in hematopoietic cell lineages.
    Type: Application
    Filed: August 5, 2019
    Publication date: March 17, 2022
    Inventors: William N. Haining, Arlene H. Sharpe, Martin Lafleur, Thao Nguyen
  • Publication number: 20220057403
    Abstract: The present invention relates, in part, to methods of treating a cancer in a subject comprising administering to the subject a therapeutically effective amount of an agent that modulates one or more biomarkers, such as inhibits one or more biomarkers listed in Table 1 and/or increases one or more biomarkers listed in Table 4, in combination with an immunotherapy.
    Type: Application
    Filed: January 9, 2020
    Publication date: February 24, 2022
    Inventors: William N. Haining, Adrienne Long, Robert Manguso
  • Patent number: 11179480
    Abstract: The invention provides in vivo methods for identifying cancer-associated immunotherapy targets.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: November 23, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: William N. Haining, Robert Manguso, Natalie Collins
  • Publication number: 20210309965
    Abstract: The present invention is based on the identification of T-cell exhaustion state-specific gene expression regulators, as well as uses thereof.
    Type: Application
    Filed: March 21, 2017
    Publication date: October 7, 2021
    Inventors: William N. Haining, Debattama SEN, E John WHERRY, Nir YOSEF, James KAMINSKI, Kristen PAUKEN
  • Patent number: 10927410
    Abstract: The present invention is based on the identification, of compositions and methods for the identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulators.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: February 23, 2021
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: William N. Haining, Arlene H. Sharpe, Jernej Godec
  • Publication number: 20200377879
    Abstract: The present invention relates, in part, to methods of treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an agent that inhibits or promotes the copy number, the expression level, and/or the activity of one or more biomarkers listed in Table 1 or a fragment thereof. Also provided herein are methods of detecting ADAR1 or ISG15 dependency in a high proliferation cell (e.g., a cancer cell). Also provided are methods of detected increased interferon signaling pathway activity in a high proliferation cell (e.g., a cancer cell). Included herein are methods of treating cancer with inhibitors of ADAR1 or ISG15. Methods of screening for such inhibitors are also provided herein. Methods of identifying the likelihood of a cancer to be responsive to an ADAR1 inhibitor are also provided.
    Type: Application
    Filed: April 2, 2018
    Publication date: December 3, 2020
    Inventors: Matthew Meyerson, William N. Haining, Jeffrey Ishizuka, Robert Manguso, Hugh Gannon
  • Publication number: 20200300857
    Abstract: The present invention relates, in part, to methods of treating a cancer in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits one or more biomarkers listed in Table 1 in combination with an immunotherapy.
    Type: Application
    Filed: July 16, 2018
    Publication date: September 24, 2020
    Inventors: William N. Haining, Robert Manguso, Adrienne Long
  • Publication number: 20200300859
    Abstract: The present invention relates, in part, to methods of treating a cancer in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits one or more biomarkers listed in Table 1, such as regulators of TNF signaling/NF-?B activation (e.g., RIPK1, BIRC2, TBK1, TRAF3, RNF31, RBCK1, OTULIN, TRAF6, TAB2, and TNIP1), in combination with an immunotherapy.
    Type: Application
    Filed: July 16, 2018
    Publication date: September 24, 2020
    Inventors: William N. Haining, Robert Manguso
  • Patent number: 10653123
    Abstract: The invention provides methods and compositions for perturbing gene expression in hematopoietic cell lineages in vivo.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: May 19, 2020
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: William N. Haining, Arlene H. Sharpe, Jernej Godec
  • Publication number: 20200149042
    Abstract: The present invention relates, in part, to methods of treating a cancer in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits one or more biomarkers listed in Table 1, such as regulators of ubiquitin proteasome pathway (e.g., STIP1 homology and U-Box containing protein 1 (STUB 1), ubiquilin-1 (UBQLN1), and heat shock protein 90 kDa beta member 1 (HSP90B 1)), in combination with an immunotherapy.
    Type: Application
    Filed: July 16, 2018
    Publication date: May 14, 2020
    Inventors: William N. Haining, Robert Manguso
  • Publication number: 20170360963
    Abstract: The invention provides in vivo methods for identifying cancer-associated immunotherapy targets.
    Type: Application
    Filed: December 22, 2015
    Publication date: December 21, 2017
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: William N. Haining, Robert Manguso, Natalie Collins
  • Publication number: 20170233808
    Abstract: The present invention is based on the identification, of compositions and methods for the identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulators.
    Type: Application
    Filed: October 16, 2015
    Publication date: August 17, 2017
    Inventors: William N. Haining, Arlene H. Sharpe, Jernej Godec
  • Publication number: 20170215392
    Abstract: The invention provides methods and compositions for perturbing gene expression in hematopoietic cell lineages in vivo.
    Type: Application
    Filed: May 27, 2015
    Publication date: August 3, 2017
    Inventors: William N. Haining, Arlene H. Sharpe, Jernej Godec